0K4 Stock Overview
Together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Akero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.62 |
| 52 Week High | US$32.78 |
| 52 Week Low | US$14.70 |
| Beta | -0.26 |
| 11 Month Change | 12.11% |
| 3 Month Change | 21.64% |
| 1 Year Change | 102.88% |
| 33 Year Change | 51.12% |
| 5 Year Change | 71.21% |
| Change since IPO | 75.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.0% | -0.7% | -0.02% |
| 1Y | 102.9% | -17.2% | 8.2% |
Return vs Industry: 0K4 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 0K4 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 0K4 volatility | |
|---|---|
| 0K4 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 0K4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0K4's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Andrew Cheng | akerotx.com |
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Akero Therapeutics, Inc. Fundamentals Summary
| 0K4 fundamental statistics | |
|---|---|
| Market cap | €2.19b |
| Earnings (TTM) | -€227.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs 0K4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K4 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$237.22m |
| Earnings | -US$237.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.8% |
How did 0K4 perform over the long term?
See historical performance and comparison